Af­ter gen­er­at­ing AS­CO fer­vor, Io­vance un­veils plans to build $75M cell ther­a­py man­u­fac­tur­ing plant

Af­ter caus­ing a stir weeks ago with its AS­CO ab­stract that hint­ed at the po­ten­tial su­prema­cy of its cell ther­a­py for dif­fi­cult-to-treat ad­vanced cer­vi­cal can­cer, Io­vance on Wednes­day said it would in­vest mil­lions in con­struct­ing a 136,000 square foot fa­cil­i­ty in Philadel­phia.

Io­vance ex­pects to shell out some $75 mil­lion over three years for equip­ment and con­struc­tion, which is ex­pect­ed to kick off in the com­ing weeks. Once com­plet­ed, the fa­cil­i­ty will man­u­fac­ture the com­pa­ny’s tu­mor in­fil­trat­ing lym­pho­cyte (TIL) prod­ucts for sev­er­al thou­sands of pa­tients an­nu­al­ly, and cre­ate sev­er­al hun­dred jobs at full ca­pac­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER